Global Expansion

With its cultivation and manufacturing base domiciled in Australia, LGP is seeking to capitalise on Australia’s international reputation for high quality, trusted products born from its leading agricultural and production practices. 

LGP has identified the UK as a highly prospective territory with the industry forecast to grow to £$1.05 billion (A$2.10 billion) by 2024, with an expected 400,000 patients being prescribed medicinal cannabis (reference: 3 Prohibition Partners, The UK Cannabis Report, p 14 - 46).

In April 2020, Little Green Pharma announced the first export of Australian medicinal cannabis products for patients to the UK. The products were distributed in the UK by Astral Health, a UK-based specialist importer and distributor of medicinal cannabis products and a subsidiary of the LYPHE Group.

Australia’s Minister for Health, the Honourable Greg Hunt said: “This first export of Australian-produced medicinal cannabis oils to the UK marks an important step in fulfilling Australia’s vision of building a global medicinal cannabis industry capable of supplying quality medicinal cannabis products to both Australian and overseas patients.”


LGP has also identified Germany as another highly prospective territory for market entry, as medicinal cannabis products have been approved for reimbursement through health insurance. To date, the main conditions for which applications have been approved (by number of patients) in Germany are pain, attention deficit hyperactivity disorder (ADHD), spasticity as a symptom of multiple sclerosis and palliative care.

Given the current lack of a domestic supply of medicinal cannabis products in Germany, the Company considers this market to be an attractive international entry point for LGP. To the extent possible, LGP intends to leverage its know-how gained from establishing distribution in Australia to support its distribution partners to establish distribution channels for its products in Germany. In addition, Little Green Pharma has established a German subsidiary as part of its future proposed strategy to facilitate the import and export of medicinal cannabis products under its own import licence and via contracted distribution services arrangements within Germany.

Further to its business development activities, LGP recently received its first commercial order of 2,400 units to be distributed to Germany. Fulfilment of this order is expected to take place following completion of the cultivation facility expansion.